Masimo - baby in hospital bed with Masimo sensor on foot

No Challenge Too Big. No Patient Too Small.

Your Trusted Partner in Neonatal Care

For over 25 years, care teams have relied on Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry to deliver accurate SpO2 and pulse rate readings—even in challenging conditions where other pulse oximeters fail. 

Today, we remain committed to protecting your most delicate patients and strive to deliver a variety of specially tailored solutions that meet their needs and help you improve outcomes.

Discover the Masimo SET® Advantage

Discover the Masimo SET® Advantage

 

More than 10 critical congenial heart disease (CCHD) studies with SET®, representing over 300,000 babies, have shown improved screening sensitivity with the use of SET® alongside clinical assessment when compared to routine physical exam alone.1-11

In an independent, peer-reviewed study, clinicians using an oxygen targeting protocol with Masimo SET® reduced ROP rates by 10% (from 12.5% to 2.5%) over five years.12

In an independent, peer-reviewed study conducted on premature neonates with an Apgar mean score of 5, Masimo Newborn Sensors were shown to post both SpO2 and pulse rate over 45 seconds faster (mean difference) than competitor technology.13

In an independent, peer-reviewed study of neonates, Masimo SET® had 86% fewer false alarms and 92% less total alarm time compared to competitor technology.14

RD SET® sensors offer best-in-class SpO2 accuracy specifications during motion: 1.5% ARMS.*

The Masimo Blue® Sensor provides accuracy specification down to 60% SpO2 and is uniquely designed for and validated on cyanotic neonatal, infant, and paediatric patients with congenital heart disease.15

In an independent, peer-reviewed neonatal study, Masimo SET® pulse oximetry identified 86% of all bradycardic events, compared to just 14% with competitor technology.14

RD SET NeoPT-500 sensors are designed with zero adhesive components, offering a soft, lightweight, and compact solution that lies comfortably on a patient’s hand or foot.

The Project That Revolutionised Neonatal Care

The Project That Revolutionised Neonatal Care

 

Our commitment to patient safety began with Project Stork, a 1992 proof of concept for Masimo SET® pulse oximetry that aimed to demonstrate its ability to help clinicians protect neonates at their most vulnerable: in the first moments of life. What we found was that SET®, combined with the expert knowledge and decision-making of clinicians like you, was poised to make a profound impact on neonatal care.

Watch the video above to learn more.

Discover a Range of Neonatal Monitoring Solutions

Discover a Range of Neonatal Monitoring Solutions

 
Masimo - infant in medical bed with sensor on forehead

O3® Regional Oximetry

Masimo - Root and Rad-97 with Canopgraphy with canula on white background

NomoLine® Capnography

Masimo - infant in medical bed with sensor on foot

rainbow Acoustic Monitoring®

 

Masimo - Placing sensor on baby arm in hospital

SpMet® Methaemoglobin Monitoring

Improve Neonatal Outcomes with SET® Pulse Oximetry

Improve Neonatal Outcomes with SET® Pulse Oximetry

 

Fill out the form below to receive more information.

By completing the above form, you are giving Masimo permission to email you about its products and services, clinical studies, events, and other information about Masimo. You hereby consent to the use of your personal information for this purpose and in accordance with Masimo’s Privacy Notice located here or at https://www.masimo.com/company/masimo/privacy. You can withdraw your consent at any time by clicking on the unsubscribe link (opt-out) contained in the emails we send to you or by emailing us at privacy@masimo.com. You may have other rights to limit the use of your information by us as described in our Privacy Notice located here. If you agree, please click on the “Submit” button below.

 

References:

  1. 1.

    Zhao et al. Lancet. 2014 Aug 30;384(9945):747-54.

  2. 2.

    Meberg A et al. J Pediatr. 2008;152:761-5.

  3. 3.

    Schena F et al. J Pediatr. 2017;183:74-79.

  4. 4.

    de-Wahl Granelli A et al. BMJ. 2009;8:338.

  5. 5.

    Ewer AK et al. Lancet. 2011;378(9793):785-94.

  6. 6.

    de-Wahl Granelli A et al. Acta Paediatr. 2007;96(10):1455-9.

  7. 7.

    Slitine N et al. Int J Neonatal Screen. 2020;6(53):30.

  8. 8.

    Gunaratne CR et al. Sri Lanka J Child Health. 2021;50(1):04-11.

  9. 9.

    Jawin V et al. PLoS One. 2015;10(9):e0137580

  10. 10.

    Hamilçikan S, Can E. J Perinat Med. 2018;46(2):203-207.

  11. 11.

    Gopalakrishnan S et al. Med J Armed Forces India. 2021;77(2):214-219.

  12. 12.

    Chow LC et al. Pediatrics. 2003;111(2):339-45.

  13. 13.

    Baquero H et al. Acta Pediatr. 2010;100:515-518.

  14. 14.

    Hay W et al. J Perinatol. 2002;360–366.

  15. 15.

    Harris B. et al. Ped Crit Care Med. 2016;17(4):315-20.

  16. *ARMS accuracy is a statistical calculation of the difference between device measurements and reference measurements. Approximately two-thirds of the device measurements fell within ± ARMS of the reference measurements in a controlled study.

For professional use. See instructions for use for full prescribing information including indications, contraindications, warnings and precautions.

PLCO-005081/PLM-13126A-1021